AstraZeneca's Symbicort Approved in China for Mild Asthma
January 26 2021 - 2:47AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Tuesday that Symbicort was approved in
China as a treatment for mild asthma in patients over the age of
12.
The U.K. pharmaceutical giant said the approval by the National
Medical Products Administration was based on the positive results
of the SYGMA 1 and SYGMA 2 Phase 3 trials. Those evaluated the
efficacy of Symbicort Turbuhaler taken, as needed, as an
anti-inflammatory reliever compared with the standard of care
therapies in mild asthma, the company said.
The company said Symbicort was already approved in China for
patients with moderate to severe asthma.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 26, 2021 02:32 ET (07:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
